Abstract
Heart failure (HF) is characterized by abnormalities in beta-adrenergic receptor (betaAR) signaling, including an increase in betaAR kinase 1 (betaARK1) levels and activity. Gene therapy using a peptide inhibitor of betaARK1 (betaARKct) in infarcted rabbit hearts has improved compromised cardiac function. To determine whether betaARK1 inhibition improves survival in a mouse model of HF induced by myocardial infarction (MI), we studied wild-type (WT) and transgenic (TG) mice overexpressing betaARKct following MI. There was no difference in infarct size. Survival of WT mice with MI was 25% at 26 weeks. In contrast, 92% of betaARKct TG mice with MI survived (P = 0.01). betaARKct TG mice with MI at 8 weeks showed significantly higher fractional shortening compared with WT mice with MI (25.1 +/- 2.7% versus 14.2 +/- 1.0%; P < 0.05). Moreover, the biochemical betaAR abnormalities in WT mice with MI were prevented in betaARKct TG mice with MI. In conclusion, betaARK1 inhibition results in a marked increase in survival and improved cardiac function in a mouse model of HF induced by MI.
MeSH terms
-
Animals
-
Coronary Stenosis / physiopathology
-
Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors*
-
Cyclic AMP-Dependent Protein Kinases / genetics
-
Cyclic AMP-Dependent Protein Kinases / therapeutic use
-
Diastole / drug effects
-
Diastole / physiology
-
Disease Models, Animal
-
Down-Regulation
-
Heart Failure / complications
-
Heart Failure / mortality*
-
Heart Failure / prevention & control*
-
Heart Rupture, Post-Infarction / etiology
-
Heart Rupture, Post-Infarction / mortality
-
Heart Rupture, Post-Infarction / physiopathology
-
Heart Rupture, Post-Infarction / prevention & control
-
Heterozygote
-
Homozygote
-
Hypertrophy, Left Ventricular / complications
-
Hypertrophy, Left Ventricular / drug therapy
-
Mice
-
Mice, Inbred C57BL
-
Mice, Transgenic / genetics
-
Myocardial Infarction / complications
-
Myocardial Infarction / mortality*
-
Myocardial Infarction / prevention & control
-
Protein Kinase Inhibitors / pharmacology*
-
Protein Kinase Inhibitors / therapeutic use*
-
Signal Transduction / genetics
-
Signal Transduction / physiology
-
Systole / drug effects
-
Systole / physiology
-
beta-Adrenergic Receptor Kinases
Substances
-
Protein Kinase Inhibitors
-
Cyclic AMP-Dependent Protein Kinases
-
beta-Adrenergic Receptor Kinases